BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ben-Zeev B, Tabib A, Nissenkorn A, Garti BZ, Gomori JM, Nass D, Goldshmidt H, Fellig Y, Anikster Y, Nevo Y, Elpeleg O, Mevorach D. Devastating recurrent brain ischemic infarctions and retinal disease in pediatric patients with CD59 deficiency. Eur J Paediatr Neurol 2015;19:688-93. [PMID: 26233519 DOI: 10.1016/j.ejpn.2015.07.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Chai JN, Azad AK, Kuan K, Guo X, Wang Y. A Splice Site Mutation Associated with Congenital CD59 Deficiency. Hematology Reports 2022;14:172-8. [DOI: 10.3390/hematolrep14020025] [Reference Citation Analysis]
2 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
3 Yuksel D, Oguz KK, Azapagası E, Kesici S, Cavdarli B, Konuskan B, Topaloglu H. Uncontrolled inflammation of the nervous system: Inherited CD59 deficiency. Neurol Clin Pract 2018;8:e18-20. [PMID: 30564502 DOI: 10.1212/CPJ.0000000000000511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Karbian N, Eshed-Eisenbach Y, Tabib A, Hoizman H, Morgan BP, Schueler-Furman O, Peles E, Mevorach D. Molecular pathogenesis of human CD59 deficiency. Neurol Genet 2018;4:e280. [PMID: 30533526 DOI: 10.1212/NXG.0000000000000280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
5 Klemann C, Kirschner J, Ammann S, Urbach H, Moske-eick O, Zieger B, Lorenz MR, Schwarz K, Doostkam S, Ehl S, Korinthenberg R. CD59 deficiency presenting as polyneuropathy and Moyamoya syndrome with endothelial abnormalities of small brain vessels. European Journal of Paediatric Neurology 2018;22:870-7. [DOI: 10.1016/j.ejpn.2018.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Kinoshita T. Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor. Seminars in Hematology 2018;55:136-40. [DOI: 10.1053/j.seminhematol.2018.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
7 Tabib A, Hindi I, Karbian N, Zelig O, Falach B, Mevorach D. Prothrombotic mechanisms in patients with congenital p.Cys89Tyr mutation in CD59. Thromb Res 2018;168:67-77. [PMID: 29929138 DOI: 10.1016/j.thromres.2018.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tabib A, Karbian N, Mevorach D. Demyelination, strokes, and eculizumab: Lessons from the congenital CD59 gene mutations. Mol Immunol 2017;89:69-72. [PMID: 28622911 DOI: 10.1016/j.molimm.2017.05.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mevorach D, Reiner I, Grau A, Ilan U, Berkun Y, Ta-shma A, Elpeleg O, Shorer Z, Edvardson S, Tabib A. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation: Eculizumab for Non-Functional CD59. Ann Neurol 2016;80:708-17. [DOI: 10.1002/ana.24770] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]